• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表观遗传学和转录组分析揭示了克隆性前列腺癌转移中保守的核心转录程序。

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

机构信息

Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Division of Molecular Oncogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.

出版信息

Mol Oncol. 2021 Jul;15(7):1942-1955. doi: 10.1002/1878-0261.12923. Epub 2021 Mar 11.

DOI:10.1002/1878-0261.12923
PMID:33576154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8253095/
Abstract

The epigenomic regulation of transcriptional programs in metastatic prostate cancer is poorly understood. We studied the epigenomic landscape of prostate cancer drivers using transcriptional profiling and ChIP-seq in four clonal metastatic tumors derived from a single prostate cancer patient. Our epigenomic analyses focused on androgen receptor (AR), which is a key oncogenic driver in prostate cancer, the AR pioneer factor FOXA1, chromatin insulator CCCTC-Binding Factor, as well as for modified histones H3K27ac and H3K27me3. The vast majority of AR binding sites were shared among healthy prostate, primary prostate cancer, and metastatic tumor samples, signifying core AR-driven transcriptional regulation within the prostate cell lineage. Genes associated with core AR-binding events were significantly enriched for essential genes in prostate cancer cell proliferation. Remarkably, the metastasis-specific active AR binding sites showed no differential transcriptional output, indicating a robust transcriptional program across metastatic samples. Combined, our data reveal a core transcriptional program in clonal metastatic prostate cancer, despite epigenomic differences in the AR cistrome.

摘要

转移性前列腺癌中转录程序的表观基因组调控机制还不甚清楚。我们通过对从单个前列腺癌患者中衍生的四个克隆转移肿瘤进行转录组分析和 ChIP-seq 分析,研究了前列腺癌驱动因子的表观基因组图谱。我们的表观基因组分析主要集中在雄激素受体(AR)上,它是前列腺癌中的关键致癌驱动因子,AR 先驱因子 FOXA1、染色质绝缘子 CCCTC 结合因子,以及组蛋白 H3K27ac 和 H3K27me3 的修饰。绝大多数 AR 结合位点在健康前列腺、原发性前列腺癌和转移性肿瘤样本中是共享的,这表明在前列腺细胞谱系中存在核心的 AR 驱动的转录调控。与核心 AR 结合事件相关的基因在前列腺癌细胞增殖的必需基因中显著富集。值得注意的是,转移性特异性的活跃 AR 结合位点没有表现出不同的转录输出,这表明在转移性样本中存在一个稳健的转录程序。综上所述,尽管 AR 顺式作用元件在表观基因组上存在差异,但我们的数据揭示了克隆性转移性前列腺癌中的一个核心转录程序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/4406f9a54af8/MOL2-15-1942-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/08d74602f0cd/MOL2-15-1942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/456f6b4b0fb3/MOL2-15-1942-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/6bdcce23b849/MOL2-15-1942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/4406f9a54af8/MOL2-15-1942-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/08d74602f0cd/MOL2-15-1942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/456f6b4b0fb3/MOL2-15-1942-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/6bdcce23b849/MOL2-15-1942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad61/8253095/4406f9a54af8/MOL2-15-1942-g005.jpg

相似文献

1
Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.表观遗传学和转录组分析揭示了克隆性前列腺癌转移中保守的核心转录程序。
Mol Oncol. 2021 Jul;15(7):1942-1955. doi: 10.1002/1878-0261.12923. Epub 2021 Mar 11.
2
Integrative epigenetic taxonomy of primary prostate cancer.原发性前列腺癌的综合表观遗传学分类。
Nat Commun. 2018 Nov 21;9(1):4900. doi: 10.1038/s41467-018-07270-2.
3
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.组蛋白去甲基化酶KDM3A调节前列腺癌细胞中雄激素受体的转录程序。
Oncotarget. 2017 May 2;8(18):30328-30343. doi: 10.18632/oncotarget.15681.
4
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.治疗后出现的神经内分泌前列腺癌中 FOXA1 顺式作用元件的重编程。
Nat Commun. 2021 Mar 30;12(1):1979. doi: 10.1038/s41467-021-22139-7.
5
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.雄激素受体增强子的使用和人类前列腺癌中的染色质调控景观。
Endocr Relat Cancer. 2019 May;26(5):R267-R285. doi: 10.1530/ERC-19-0032.
6
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.蛋白质精氨酸甲基转移酶5作为雄激素受体的表观遗传激活剂,促进前列腺癌细胞生长。
Oncogene. 2017 Mar 2;36(9):1223-1231. doi: 10.1038/onc.2016.287. Epub 2016 Aug 22.
7
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.c-Myc 拮抗前列腺癌细胞中雄激素受体的转录活性,影响关键基因网络。
EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.
8
Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF.整合分析确定了一类雄激素反应基因,这些基因受 CTCF 介导的短组合长程机制调控。
Nucleic Acids Res. 2012 Jun;40(11):4754-64. doi: 10.1093/nar/gks139. Epub 2012 Feb 16.
9
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.MYC 通过扰乱雄激素受体靶基因的转录暂停释放来驱动侵袭性前列腺癌。
Nat Commun. 2022 May 13;13(1):2559. doi: 10.1038/s41467-022-30257-z.
10
Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.AP-1在前列腺成纤维细胞雄激素受体顺反子组中的细胞谱系特异性及作用
Mol Cell Endocrinol. 2017 Jan 5;439:261-272. doi: 10.1016/j.mce.2016.09.010. Epub 2016 Sep 12.

引用本文的文献

1
TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.TRIM33缺失会降低雄激素受体转录输出和H2BK120泛素化。
Commun Biol. 2025 Jul 11;8(1):1043. doi: 10.1038/s42003-025-08449-2.
2
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.表观遗传学分析确定了转移性去势抵抗性前列腺癌的内分泌抵抗标志物和治疗选择。
Cell Rep Med. 2025 Jul 15;6(7):102215. doi: 10.1016/j.xcrm.2025.102215. Epub 2025 Jul 2.
3
Comprehensive functional annotation of ESR1-driven enhancers in breast cancer reveals hierarchical activity independent of genomic and epigenomic contexts.

本文引用的文献

1
Prostate cancer reactivates developmental epigenomic programs during metastatic progression.前列腺癌在转移进展过程中重新激活发育表观基因组程序。
Nat Genet. 2020 Aug;52(8):790-799. doi: 10.1038/s41588-020-0664-8. Epub 2020 Jul 20.
2
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.非编码突变靶向前列腺癌 FOXA1 丛的顺式调控元件。
Nat Commun. 2020 Jan 23;11(1):441. doi: 10.1038/s41467-020-14318-9.
3
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
对乳腺癌中ESR1驱动的增强子进行全面功能注释,揭示了独立于基因组和表观基因组背景的分层活性。
Genome Res. 2025 Jul 1;35(7):1530-1543. doi: 10.1101/gr.280320.124.
4
Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer.单细胞转录组分析揭示去势抵抗性转移性前列腺癌中的长链非编码RNA图谱。
NPJ Genom Med. 2024 Feb 23;9(1):14. doi: 10.1038/s41525-024-00401-3.
5
Compartmentalization of androgen receptors at endogenous genes in living cells.活细胞内内源基因雄激素受体的区室化。
Nucleic Acids Res. 2023 Nov 10;51(20):10992-11009. doi: 10.1093/nar/gkad803.
6
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.原发前列腺癌中广泛的雄激素受体增强子异质性是转录多样性和转移潜能的基础。
Nat Commun. 2022 Nov 30;13(1):7367. doi: 10.1038/s41467-022-35135-2.
7
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.循环肿瘤 DNA 中的核小体模式揭示了晚期前列腺癌表型的转录调控。
Cancer Discov. 2023 Mar 1;13(3):632-653. doi: 10.1158/2159-8290.CD-22-0692.
8
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.前列腺癌表观遗传可塑性和增强子异质性:分子原因、后果和临床意义。
Adv Exp Med Biol. 2022;1390:255-275. doi: 10.1007/978-3-031-11836-4_15.
9
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.从组学到多组学方法深入分析前列腺癌的分子机制。
Int J Mol Sci. 2022 Jun 3;23(11):6281. doi: 10.3390/ijms23116281.
转移性去势抵抗性前列腺癌的基因组图谱揭示了多种具有潜在临床影响的独特基因型。
Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
4
Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.染色质结构域分区揭示了原发性前列腺肿瘤中主转录调控因子的体细胞突变和风险变异的趋同。
Cancer Cell. 2019 Dec 9;36(6):674-689.e6. doi: 10.1016/j.ccell.2019.10.005. Epub 2019 Nov 14.
5
Deciphering essential cistromes using genome-wide CRISPR screens.利用全基因组 CRISPR 筛选技术解析核心调控元件组。
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25186-25195. doi: 10.1073/pnas.1908155116. Epub 2019 Nov 14.
6
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.谱系可塑性在前列腺癌治疗抵抗中的作用。
Clin Cancer Res. 2019 Dec 1;25(23):6916-6924. doi: 10.1158/1078-0432.CCR-19-1423. Epub 2019 Jul 30.
7
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.分子谱分析对治疗抵抗的转移性去势抵抗性前列腺癌的多种表型进行分层。
J Clin Invest. 2019 Jul 30;129(10):4492-4505. doi: 10.1172/JCI128212.
8
Integrative epigenetic taxonomy of primary prostate cancer.原发性前列腺癌的综合表观遗传学分类。
Nat Commun. 2018 Nov 21;9(1):4900. doi: 10.1038/s41467-018-07270-2.
9
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.转移性前列腺癌的基因组特征与结构变异
Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019.
10
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.帕比司他联合比卡鲁胺再挑战治疗去势抵抗性前列腺癌的表观遗传学治疗。
Clin Cancer Res. 2019 Jan 1;25(1):52-63. doi: 10.1158/1078-0432.CCR-18-1589. Epub 2018 Sep 17.